Klaria Pharma Holding AB to be listed on Nasdaq Stockholm First North

Klaria’s business idea lies in the development and commercialization of innovative and patented products with clear competitive advantage in the therapy areas of migraine and acute pain related to cancer (breakthrough cancer pain).  In total, the global yearly market for both areas combined is in excess of 7 billion USD and growth in both areas will be high.  The common threads in both areas of acute pain management are large and growing patient groups, acute and severe pain and a clear demand from patients and regulators for improved products with both more reliable absorption and a faster onset of relief than today’s therapies can offer.

‘The ambition is to create world-leading products in the area of acute pain management’ says Dr. Scott Boyer, CEO, Klaria

The demand for therapies that treat pain related to migraine and breakthrough cancer pain is expected to expand dramatically in the coming years.  The driving forces behind this expansion of both patient groups is the demand by these patients (and healthcare systems) for simpler, faster-acting, more reliable products that can be produced at a reasonable cost.  This combination will result in much improved compliance and many fewer emergency room visits, thereby lowering the overall burden on patients, their families and the health systems.

Migraine
Approximately 12 percent of the world’s population suffers from recurring migraine attacks. However, many neither acknowledge the presence nor the enormous personal and economic impact of migraine and it is thus under-diagnosed and poorly managed.   The highest percentage of migraine patients are women in their 40’s, of which nearly a quarter have frequently-recurring migraine attacks.  

More information is available at klaria.com/en/our-focus/migraine/.

‘Beyond the pain management we also want to give the patient back a sense of control.  For patients that are affected by recurrent and severe bouts of pain, the sense of control is often just as valuable as the actual pain management.’  Says Dr. Scott Boyer, CEO, Klaria.

Breakthrough Cancer Pain
Statistically, in Sweden about a third of all people will be diagnosed with cancer in their lifetime.  A majority of those cancer patients will unfortunately also experience pain related to their cancer that will require a prescription medication to manage the pain.  Of those patients receiving medication to manage pain, many also experience recurrent, acute and severe bouts of pain that cannot be managed by their normal pain medication.  These ‘breakthrough cancer pain’ episodes last from 3 to 30 minutes and are often sudden and severe.  In combination with the underlying cancer and the worry that severe pain can come suddenly and without warning contributes to many patients feeling helpless and lacking control of their symptoms. This combination leads ultimately to a significantly lower quality of life.  These issues are what Klaria’s products are designed to address.  

More information is available at klaria.com/en/our-focus/cancer-related-pain/.

’By combining our unique drug delivery platform with proven drugs, we will be able to offer a medication the will allow patients never to have to use a nasal spray, swallow a tablet or to inject themselves.  These are exactly the type of products patients, healthcare professionals and regulatory authorities are asking for,’ says Dr. Scott Boyer, CEO, Klaria.

Technology
The drug delivery platform itself is based on a patented, alginate-based polymer film that is like a small postage stamp.  The film is attached to the inside of the mouth and the active drug distributes from the film directly through the lining of the mouth to the bloodstream. This method provides many advantages for the patient including a much shorter time for absorption and thus a shorter time to effect, more reliable effect from dose to dose and simplicity in administration.  For Klaria, the use of proven drugs but in a significantly improved format means this combination will take less time to reach the market with lower development costs and a significantly lower risk regarding the probability of successful clinical development.